LRT Capital Management LLC Acquires 931 Shares of IDEXX Laboratories, Inc. $IDXX

LRT Capital Management LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 78.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,119 shares of the company’s stock after buying an additional 931 shares during the period. LRT Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,434,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after purchasing an additional 86,040 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at about $3,666,459,000. State Street Corp boosted its holdings in shares of IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after buying an additional 138,956 shares in the last quarter. Geode Capital Management LLC grew its position in shares of IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $560.88 on Friday. The business’s 50-day moving average is $563.06 and its two-hundred day moving average is $627.69. The company has a market capitalization of $44.24 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on IDXX shares. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.